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Objective. The EFEMP1 gene encoding fibulin 3 is specifically expressed in the superficial zone (SZ) of articular cartilage. The aims of this study were to examine the expression patterns of fibulin 3 in the knee joints during aging and during osteoarthritis (OA) and to determine the role of fibulin 3 in the pathogenesis of OA.
Methods. Immunohistochemical analysis was performed on normal and OA knee cartilage samples from humans and mice. Experimental OA was induced in wildtype and fibulin 3 2/2 mice, and the severity of OA was evaluated by histologic scoring. To examine fibulin 3 function, human chondrocyte monolayer cultures were transfected with small interfering RNA (siRNA), followed by quantitative polymerase chain reaction and Western blot analyses. Human bone marrow-derived mesenchymal stem cells (BM-MSCs) were transduced with an EFEMP1 lentivirus and analyzed for markers of chondrogenesis.
Results. Fibulin 3 was specifically expressed in the SZ of normal knee joint cartilage from humans and mice, and the expression levels declined with aging. Both agingrelated OA and experimental OA were significantly more severe in fibulin 3 2/2 mice compared with wild-type mice.
Fibulin 3 expression was high in undifferentiated human BM-MSCs and decreased during chondrogenesis. Suppression of fibulin 3 by siRNA significantly increased the expression of SOX9, type II collagen, and aggrecan in human articular chondrocytes, while overexpression of fibulin 3 inhibited chondrogenesis in BM-MSCs. Conclusion. Fibulin 3 is specifically expressed in the SZ of articular cartilage and its expression is reduced in aging and OA. Fibulin 3 regulates differentiation of adult progenitor cells, and its aging-related decline is an early event in the pathogenesis of OA. Preventing agingassociated loss of fibulin 3 or restoring it to normal levels in SZ chondrocytes has the potential to delay or prevent the onset of OA.
Osteoarthritis (OA) is the most prevalent joint disease, and aging represents a major risk factor (1) (2) (3) . All joint tissues are involved in the OA process, but degradation of the articular cartilage appears to be a principal factor in OA initiation and progression (4, 5) . Pathogenetic pathways that mediate cartilage destruction in established OA have been characterized, and these include cartilage cell death, abnormal chondrocyte differentiation, degradation and calcification of the cartilage extracellular matrix (ECM), angiogenesis, and the production of inflammatory mediators (6) . Targeting these mechanisms in established or advanced disease has thus far not been successful in clinical trials (7, 8) .
Among the earliest changes in the joints during aging is disruption of the articular cartilage surface, which may be a critical event in triggering the cartilage remodeling process that ultimately manifests as OA (6) . The cartilage superficial zone (SZ) is unique in its biomechanical function and ECM composition. The cells in the SZ are also distinguishable from cells in the middle and deep zones on the basis of different gene and protein expression patterns (9) . Furthermore, the SZ contains a high concentration of multipotent mesenchymal progenitor cells (10, 11) .
Understanding of the mechanisms that control the unique differentiation status of SZ cells is limited. It has been suggested that SZ cells resemble the joint interzone cells that are involved in joint formation during development (12, 13) . Our recent studies showed that the chromatin protein high mobility group box chromosomal protein 2 (HMGB-2) is uniquely expressed in the SZ, and its expression declines with aging in human and mouse joints. Deletion of the Hmgb2 gene in mice leads to increased severity of aging-related OA (14) . HMGB-2 supports SZ cell survival through interactions with Wnt signaling (15) and maintains the immature differentiation status of these cells (16) . To further elucidate the functions of HMGB-2, we performed gene expression analyses and identified fibulin 3 as an HMGB-2-regulated gene.
Fibulin 3 is 1 of 7 members of the mammalian fibulin family of glycoproteins (17) . The fibulin 3 gene, also referred to as EFEMP1, encodes a 493-amino acid protein (18) . The functions of fibulin include basement membrane organization and elastic fiber formation, a specific function of the "elastic" fibulins 3, 4, and 5 (17) . Mice deficient in fibulin 3 (fibulin 3 2/2 mice) show defects in elastic fibers and microfibrils (19) (20) (21) . These mice also exhibit reduced fertility and an early onset of aging-associated phenotypes, including decreased body mass and bone density, lordokyphosis, reduced hair growth, generalized fat, and muscle and organ atrophy (20) . The objectives of this study were to analyze the expression patterns of fibulin 3 in normal and OA knee joint tissue and to determine the role of fibulin 3 in the maintenance of joint homeostasis and pathogenesis of OA.
MATERIALS AND METHODS
Assessment of human articular cartilage and chondrocytes. Human knee joints were obtained from subjects at the time of autopsy, with approval provided by the Scripps Human Subjects Committee. The joints were processed within 72 hours postmortem. Safranin O-stained sections of normal and OA knee joint cartilage were graded with the Mankin system (22) , in which a score of 0 indicates normal cartilage, scores of 1-4 indicate cartilage with mild-to-moderate OA, and scores of $5 indicate cartilage with severe OA (14) . Chondrocytes were isolated from normal human knee cartilage and cultured, as described previously (23) . The average age of the donors was a mean 6 SD 52 6 7 years, and the average body mass index was 27 6 6 kg/m 2 . The chondrocytes were used in the experiments after they had reached confluence (2-3 weeks in primary culture). We used monolayer cultures at a high cell density, which maintains differentiation and allows transfection of small interfering RNA (siRNA). Although this approach helps facilitate these treatments, the monolayer system does have some limitations, such as its inability to provide a native ECM environment.
Assessment of the knee joints of aging mice. All animal experiments were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute. Fibulin 3 2/2 mice, on a 129Sv/J-C57BL/6m genetic background, were generated by McLaughlin and colleagues (20) . Age-and sex-matched wild-type (WT) mice of the same parental lineage were included in each experiment. Each group included 50% male mice and 50% female mice. Knee joints were collected from WT mice and fibulin 3 2/2 mice (age 4 months, n 5 10 per group; age 6 months, n 5 10 per group; age 9 months, n 5 10 per group; age 12 months, n 5 7 per group). The joints were processed, stained with Safranin O-fast green, and histologically graded in a manner as described previously (24) .
Assessment of the knee joints of mice with experimental OA. Experimental OA was induced in 2-month-old mice (n 5 10 WT, n 5 10 fibulin 3 1/2 , and n 5 10 fibulin 3
2/2
) and 6-month-old mice (n 5 10 WT and n 5 10 fibulin 3
) by destabilization of the medial meniscus (DMM) surgery, involving transection of the medial meniscotibial ligament and the medial collateral ligament in the right knee (24) . The left knee was not subjected to surgery, and thus was used as a control. The animals were euthanized at 10 weeks after the knee surgery. For histologic analysis, the knee joints were fixed, decalcified, and paraffin embedded as described previously (24) . Serial sections were stained with Safranin O-fast green and examined for histopathologic changes using a semiquantitative scoring system (24) .
Western blotting. Cell extracts were prepared with lysis buffer. Protein concentrations were measured using a BCA protein assay kit (Bio-Rad). Equal amounts of protein (10 mg per lane) were applied.
Normal and OA human cartilage tissue was homogenized in TRIzol (Invitrogen) at room temperature. After the addition of chloroform, samples were vortexed vigorously and centrifuged for 15 minutes at 12,000g at 48C. Both the interphase and organic phase were collected, followed by the addition of 100% ethanol. After centrifugation, the supernatant was collected for protein isolation. Proteins were precipitated by the addition of isopropanol and diluted in 6M urea-2% sodium dodecyl sulfate.
Quantitative Western blotting was performed with a LiCor immunofluorescence detection system as described previously (25) . The following antibodies were used: sheep anti-fibulin 3 (at a dilution of 1/1,000) (AF6235; R&D Systems), goat anticaspase 3 (at a dilution of 1/500) (sc-1226; Santa Cruz Biotechnology), rabbit anti-V5 tag (at a dilution of 1/1,000) (ab15828, Abcam), or mouse anti-GAPDH (at a dilution of 1/5,000) (AM4300; Ambion). Integrated intensity values (K counts) of the proteins of interest were normalized to those of GAPDH.
Immunohistochemistry. Tissue sections were prepared as described previously (26) . Antigen retrieval was performed by incubation with hyaluronidase for 60 minutes at 378C. The following antibodies were used: antibody to rabbit fibulin 3 (5 mg/ ml) (a gift from Takako Sasaki), antibody to rabbit proteoglycan 4 (PRG-4; also known as SZ protein [SZP]) (5 mg/ml) (LSB8236; LSBio), or polyclonal antibody specific for the p85 fragment of poly(ADP-ribose) polymerase (PARP) (Promega).
In cartilage from mouse knee joints, 3 images were obtained to show the center of the femoral condyle that is not covered by the menisci, as well as the medial femoral condyle and lateral femoral condyle. The total number of chondrocytes was counted, and then the total number of cells positive for fibulin 3, PRG-4/SZP, or PARP-p85 was counted in each section. Results are expressed as the percentage of fibulin 3-positive, PRG-4/SZP-positive, or PARP-p85-positive cells.
Differentiation of bone marrow-derived mesenchymal stem cells (BM-MSCs). Human BM-MSCs were purchased from Lonza. BM-MSC pellets (3 3 10 5 cells/pellet) were cultured in 0.5 ml chondrogenic medium (Lonza), supplemented with transforming growth factor b3 (10 ng/ml) and bone morphogenetic protein 2 (100 ng/ml). Medium was changed every 3 days. Pellets were collected at 3 weeks for histologic analysis and quantitative polymerase chain reaction (PCR).
Immunocytochemistry. Human articular chondrocytes and BM-MSCs were cultured in 8-well chamber slides, fixed in 2% formaldehyde and acetone. Cells were incubated with rabbit anti-fibulin 3 antibody (5 mg/ml) (a gift from Takako Sasaki) at room temperature for 1 hour. Thereafter, the cells were washed with phosphate buffered saline (PBS) and incubated with biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories).
Cell transfection with siRNA. Human articular chondrocytes were transfected with 50 nM Stealth RNA targeting fibulin 3 (Invitrogen) or, as a control, Stealth RNAi Negative Control Medium GC (Invitrogen). Transfections were carried out using Lipofectamine 2000 reagent (Invitrogen). 
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HASEGAWA ET AL Assessment of cell viability by MTT assay. Following transfection of the human articular chondrocytes with siRNA and incubation for 72 hours, cell viability was determined using an MTT assay, as described previously (25) . PBS containing 5 mg/ml MTT was added to each well. The plates, under conditions protected from light, were then incubated for 5 hours. Thereafter, the medium was removed and precipitates were resuspended in 200 ml DMSO. The absorbance at 540 nm was measured using a plate reader. Experiments were performed in triplicate.
Preparation of lentiviral vector. In order to prepare a lentiviral construct expressing the EFEMP1 gene, pcDNA6V5/ His was used. Open-reading frame (ORF) regions were amplified from the complementary DNA (cDNA) of human chondrocytes. PCR products and vectors were digested with Nhe I and Kpn I (New England Biolabs), and ligated into the vector using Nhe I and Kpn I sites. To prepare the lentiviral expression construct, the EFEMP1 ORF was amplified from the established constructs and sequenced. The pENTR possessing the EFEMP1 ORF and pLenti4/V5-DEST (Invitrogen) were recombined using Gateway LR Clonase II Enzyme Mix (Invitrogen), and then recombined pLenti4/V5-EFEMP1 was cloned and purified from Stbl3-competent cells. As a control lentivirus, pLenti4/V5-GW/LacZ was cloned and purified from Stbl3-competent cells.
Overexpression of fibulin 3 by cDNA transfection of human chondrocytes. The pcDNA6-EFEMP1 was generated as described above, and 1 mg DNA was transfected into human articular chondrocytes using 2.5 ml of Lipofectamine LTX reagent (Invitrogen). A pcDNA6-empty vector was transfected as a control. Twenty-four hours after transfection, cells were harvested for quantitative PCR and Western blot analyses.
Quantitative PCR. Total RNA was extracted from monolayer or pellet cultures, and oligo(dT)-primed cDNA was prepared using TaqMan reverse transcription reagents (Invitrogen). The levels of EFEMP1, SOX9, ACAN, Col2a1, and GAPDH gene expression were assessed using TaqMan primers and probes (Applied Biosystems), and values were normalized to those for GAPDH.
Statistical analysis. Summary statistics are reported as the mean 6 SEM. Statistically significant differences between 2 groups were determined by Mann-Whitney U test (nonparametric) or Student's t-test (parametric). Differences among 3 groups were determined by Kruskal-Wallis test (nonparametric one-way analysis of variance) or Tukey-Kramer test (parametric). P values less than 0.05 were considered statistically significant.
RESULTS
Expression of fibulin 3 in normal, aging, and OA cartilage. In normal cartilage (Mankin grade 0) from young donors (mean 6 SD age 27 6 5.4 years [range 23-36 years]; n 5 5), fibulin 3 expression was localized to the SZ and the upper middle zone ( Figures 1A and D) . Fibulin 3 was observed to be intracellularly localized as well as present in the ECM. In contrast, expression of fibulin 3 was much lower in nonfibrillated cartilage (i.e., mild OA) from older human donors (mean 6 SD age 73.5 6 5.0 years [range 68-81 years]; n 5 6) ( Figures 1B and E) . Cartilage specimens with more severe OA from older donors (mean 6 SD age 78.8 6 9.9 years [range 63-90 years]; n 5 6) had no SZ layer and showed increased expression of fibulin 3 along vertical clefts in the middle zone. Moreover, most of the cells in the chondrocyte clusters in these samples were positive for fibulin 3 ( Figures 1C and F) . Low fibulin 3 expression was observed in normal-appearing cartilage from the same donors with OA.
In determining the percentage of fibulin 3-positive cells in the cartilage samples, we found a significant reduction in fibulin 3-positive cells in the SZ of the cartilage of aging donors and an increase in fibulin 3-positive cells in the middle zone of OA cartilage ( Figure 1G ), which appears to be attributable to the positive cells present in chondrocyte clusters. We also performed Western blotting of the cartilage tissue, with the results showing that fibulin 3 protein levels were significantly increased (P , 0.01) in human OA cartilage as compared with normal cartilage (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.39963/abstract).
The expression of fibulin 3 was also analyzed in the knee joints from 4-, 6-, 9-, and 12-month-old C57BL/6J mice. In normal knee joints from 4-month-old mice, fibulin 3 was localized to the SZ and upper middle zone ( Figures  2A and B) . Fibulin 3 was also expressed in the superficial layer of cells in the menisci and in the synovial lining (Figures 2C and D) . The number of fibulin 3-positive cells in the mouse cartilage was decreased with aging. In the articular cartilage from 12-month-old mice, fibulin 3-positive cells were almost completely absent ( Figures 2E-H and  M) . A reduction in fibulin 3-expressing cells was also observed in the menisci and synovium.
To address the OA-related changes in fibulin 3 expression, the knee joints from C57BL/6J mice were examined at 2, 4, 8, and 12 weeks after the induction of experimental OA by transection of the medial meniscotibial ligament and the medial collateral ligament. Fibulin 3 expression in the articular cartilage from the center of the femoral condyle, a site that is not covered by the menisci, decreased with longer time after surgery (Figures 2I-K and N) and with increasing severity of OA. Moreover, expression of fibulin 3 was increased in the chondrocyte clusters and osteophytes from the OA knee joints (Figures 2L and N) .
Experimental OA and aging-related changes in fibulin 3-deficient mice. Two-month-old WT, fibulin 3 ( Figure 3A ). Histologic scores of cartilage degeneration in the mice subjected to DMM surgery were significantly increased in fibulin 3 2/2 mice as compared with WT and fibulin 3 1/2 mice ( Figure 3A) . In 6-month-old WT and fibulin 3 2/2 mice, the severity of experimental OA was higher than that observed in 2-month-old mice, and was higher in fibulin 3 2/2 mice than that in WT mice. These results suggest that fibulin 3 deficiency leads to increased severity of experimental OA in both immature and mature mouse knee joints.
To examine whether deletion of the fibulin 3 gene impairs cartilage homeostasis and leads to increased severity of aging-related OA, we analyzed the knee joints from 10 WT mice and 10 fibulin 3 2/2 mice at ages 6, 9, and 12 months. The knees of WT mice were almost normal at age 6 months, and only a mild reduction in Safranin O staining was observed at age 9 months. In contrast, the knees of fibulin 3 2/2 mice (on the same genetic background as the WT mice) showed reduced Safranin O staining at age 6 months. Moreover, histologic Mankin scores of OA severity were significantly different between WT mice and fibulin 3 2/2 mice at ages 9 months and 12 months ( Figure 3B ). These results suggest that deletion of the fibulin 3 gene leads to an earlier onset and increased severity of aging-related OA.
Cellularity and SZP-expressing cells in mouse knees. The SZP-positive cells located in the first 3-4 cell layers of the full-thickness femoral articular cartilage were counted as SZ cells. Cartilage from fibulin 3 2/2 mice contained significantly fewer SZP-positive cells compared with cartilage from WT mice ( Figures 4A and B) . In addition, the articular cartilage was stained for the presence of PARP-p85, using an antibody that specifically detects the 85-kd fragment of PARP resulting from caspase cleavage and that does not detect the 116-kd intact PARP molecule. More PARP-p85-positive cells were detected in fibulin 3 2/2 mice than in WT mice ( Figures 4C and D) . , and fibulin 3 2/2 mice was assessed for histologic severity of OA at 10 weeks after DMM surgery. B, Top, Safranin O staining was performed to assess age-related changes in the knee cartilage from 6-, 9-, and 12-month-old WT and fibulin 3 2/2 mice from the same genetic background. Representative results are shown. In a fibulin 3 2/2 mice at age 9 months, cell death in the cartilage layer was observed (arrowheads). Bottom, Mankin scores of OA severity were determined in each age group. In A and B, original magnification 3 10. Bars 5 200 mm. Values are the mean 6 SEM score in 10 mice per group (all surgically induced OA groups and mice at ages 6 and 9 months) or 7 mice per group (mice at age 12 months). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39963/abstract. To further examine the relationship between fibulin 3 expression and chondrogenic differentiation, we analyzed BM-MSCs during chondrogenesis. Fibulin 3 was highly expressed at 1 week following the induction of chondrogenesis, whereas at 2 and 3 weeks, fibulin 3 expression was reduced as the chondrogenic differentiation progressed. Interestingly, the areas in the chondrogenic pellets that displayed strong glycosaminoglycan production, as visualized by Safranin O staining, showed reduced expression of fibulin 3 (see Supplementary Figure 2C , http://onlinelibrary. wiley.com/doi/10.1002/art.39963/abstract). These results demonstrate that the fibulin 3 expression pattern is inversely correlated with the differentiation status of BM-MSCs.
Role of fibulin 3 in regulation of chondrocyte survival and phenotype. To determine whether fibulin 3 is involved in regulating the survival or differentiation of chondrocytes, we suppressed fibulin 3 expression in human articular chondrocytes using siRNA ( Figure 5 ). There was a significant increase in the expression of active caspase 3 and a reduction in chondrocyte viability following fibulin 3 knockdown (Figures 5A and B) . Furthermore, quantitative PCR showed that the expression levels of SOX9 and ACAN messenger RNA (mRNA) were significantly increased at 48 hours after treatment of the articular chondrocytes with fibulin 3-specific siRNA ( Figure 5C ). At 72 hours, Col2a1 and ACAN mRNA expression levels were also significantly increased ( Figure 5D ).
To extend these findings, we transiently overexpressed fibulin 3 in human articular chondrocytes ( Figure  5E ). In chondrocytes overexpressing fibulin 3, the levels of SOX9 mRNA were significantly decreased ( Figure 5F ). Levels of the chondrogenic markers ACAN and Col2a1 were also decreased, but they were not statistically significantly lower than those in mock-transfected control cells.
To investigate the role of fibulin 3 during chondrogenesis, BM-MSCs were transduced with a lentivirus encoding EFEMP1 (LV/EFEMP1) or with a control lentivirus expressing LacZ (LV/LacZ). At day 21 after transduction, the LV/LacZ-transduced control pellets showed high Safranin O staining, whereas the LV/EFEMP1-transduced pellets were negative for Safranin O staining (loss of Safranin O staining being indicative of greater glycosaminoglycan loss). Results of quantitative PCR showed that expression of the ECM genes Col2a1, ACAN, and SOX9 was suppressed in LV/EFEMP1-transduced pellets compared with control LV/LacZ-transduced pellets ( Figure 6 ). These results suggest that overexpression of fibulin 3 inhibits chondrogenesis in human BM-MSCs.
DISCUSSION
Aging is a major risk factor for OA, and among the earliest lesions that emerge during the development OA is disruption of the SZ of articular cartilage (27) , but underlying mechanisms remain to be elucidated. The SZ is unique among the cartilage layers in that it is distinguished by the presence of large numbers of cells with markers and functions of adult stem cells (28, 29) and by the production of SZP, an important joint lubricant (29) . The structural defects in the SZ appear to be a consequence of cell depletion in this area. In previous studies, we identified the chromatin protein HMGB-2 as an SZ-specific protein and showed that it regulates SZ cell survival and differentiation (14) (15) (16) . Analysis of gene expression patterns in cells from WT mice and Hmgb2-deficient mice showed that fibulin 3 levels are most significantly reduced in Hmgb2-deficient mice.
The fibulin family includes 6 ECM proteins that are localized in basal membranes, stroma, and ECM fibers, mediating cell-to-cell and cell-to-matrix communication (17) . Fibulins are thought to provide organization and stabilization to ECM structures during organogenesis and vasculogenesis (17) . Fibulin 3-knockout mice display early aging phenotypes (20) . Fibulin 3 is expressed in cartilage and bone structures in the mouse embryo (18) , and fibulin 3 peptides are potential biomarkers for the diagnosis of OA (30) . However, no studies had yet characterized the expression and function of fibulin 3 in the joints of adult subjects.
The results of the present study demonstrate that fibulin 3 expression is uniquely restricted to cells in the SZ in normal mature human and mouse articular cartilage. Fibulin 3 is also expressed in the superficial or lining cell populations of the menisci and synovium. Recent studies indicated that these regions harbor adult stem cells (28, 31, 32) .
The process of aging in the joints of humans and mice is associated with reduced fibulin 3 expression in the articular cartilage, where it is normally expressed only in the SZ. However, in OA-affected cartilage, cells in the chondrocyte clusters are strongly positive for fibulin 3, as was shown by immunhistochemistry. This accounts for the increase in fibulin 3 levels in OA joints compared with normal joints in Western blot analyses of whole cartilage protein extracts.
PRG-4/SZP has a distribution similar to that of fibulin 3 in the articular cartilage, and is involved in cartilage and joint homeostasis (29, 33) . The present results show that fibulin 3 2/2 mice had significantly fewer PRG-4/SZPpositive cells compared with WT mice. Mice lacking Prg4 have normal joint development; however, as the mice age, abnormal protein deposits appear on the cartilage surface and underlying SZ chondrocytes disappear (29) . We observed a correlation between the reduction and loss of fibulin 3 and reduction and loss of PRG-4/SZP expression in the SZ of articular cartilage. The aging-related loss of fibulin 3 expression in the cartilage surface was associated with a reduction in SZ cellularity and increased apoptosis in fibulin 3 2/2 mice. Our in vitro studies evaluating the effects of fibulin 3 knockdown in chondrocytes demonstrated a reduction of cell viability.
Since expression of fibulin 3 is restricted to the SZ of articular cartilage that contains progenitor cells (28, 31, 32, 34) , we analyzed fibulin 3 expression in undifferentiated human BM-MSCs and differentiated human articular chondrocytes and found that fibulin 3 was more highly expressed in BM-MSCs. Furthermore, our in vitro studies of chondrogenesis revealed that fibulin 3 protein levels were reduced with progressive differentiation of BM-MSCs.
To address whether fibulin 3 is involved in chondrocyte differentiation, we suppressed fibulin 3 expression in articular chondrocytes using specific siRNA, and found that the expression of the chondrogenic markers Col2a1, ACAN, and SOX9 was increased. Inversely, we found decreased expression of SOX9 following fibulin 3 overexpression. These results suggest that fibulin 3 has a role in maintaining the immature status of cells in the SZ. These findings are consistent with observations of the inhibition of chondrogenesis by fibulin 3 overexpression in the murine progenitor cell line ATDC-5 (35) . The precise mechanisms by which fibulin 3 regulates these cell functions remain to be elucidated. Proteins that are known to interact with fibulin 3 include tissue inhibitor of metalloproteinases 3 (TIMP-3), an ECM-bound protein that regulates matrix composition and inhibits angiogenesis (36) . TIMP-3 is the only TIMP that firmly binds to the ECM (36) . Similar to fibulin 3, TIMP-3 is also most strongly expressed in the cartilage surface (36) .
In conclusion, we have demonstrated that fibulin 3 is specifically expressed in the SZ of mature human and mouse articular cartilage, and its expression is profoundly reduced with increasing age. Fibulin 3 has a role in maintaining the immature status of cells in the cartilage SZ. The loss of fibulin 3 is linked to the loss of SZ chondrocytes and compromises the integrity of the cartilage surface. Prevention of the loss of fibulin 3 expression in SZ chondrocytes or restoration to normal levels might serve as potential therapeutic targets in the management of patients with OA.
